rTMS (repetitive transcranial magnetic stimulation) for Tinnitus: What Does the Evidence Show?
Brain Stimulation · Ranked #10 on our Top 10 (weighting-sensitive)
Current evidence
Statistically real but clinically small — and whether any benefit lasts to 6 months is disputed between the major analyses.
Evidence strength: Limited (2/5) · Tier 3 — experimental/emerging · Evidence independence: Primarily independent.
Magnetic pulses applied over auditory/prefrontal cortex in clinic sessions, usually daily for 1–4 weeks. FDA-cleared TMS systems exist for depression/OCD; tinnitus use is off-label/investigational.
Did tinnitus loudness improve?
None shown. Loudness/psychoacoustic effects inconsistent; 2020 meta-analysis found no significant effect on loudness measures.
Did tinnitus distress improve?
Limited. Beats sham in the weeks after treatment (2025 meta: THI −11.5 post, −11.0 at 1 month across 16 RCTs). At 6 months the meta-analyses DISAGREE: 2020 (29 RCTs) found a small significant effect (−6.53), 2025 found none (−4.26, NS) — and even the significant estimates sit at/below the ~7-point meaningfulness threshold.
Loudness means the tinnitus percept itself became quieter (psychoacoustic matching or loudness ratings). Distress means questionnaire scores such as THI/TFI, sleep, anxiety or quality of life improved — the sound may be unchanged. A THI/TFI improvement is never evidence the tinnitus got quieter.
How strong is the evidence?
Many RCTs but small effects at/below clinical meaningfulness, disputed durability, and guideline advice against routine use: 2/5.
Has the result been independently replicated?
Conflicting results. Independent replication attempted and discordant: Folmer 2015 positive vs Landgrebe 2017 multicenter negative; metas driven by heterogeneous small trials.
What are the limitations?
- 6-month durability disputed between meta-analyses; effect sizes at/below clinical meaningfulness
- Huge protocol heterogeneity
- Guideline recommends against routine use
What should patients know about safety?
Safety evidence: Moderate. Generally safe; rare seizure risk; scalp discomfort and headache common.
Is it available?
Regulatory status: Investigational for tinnitus (off-label). No TMS system carries a tinnitus indication; AAO-HNSF 2014 recommends against routine TMS for tinnitus.
Availability: Off-label at some centers; research settings · Europe: Research + selected clinics · Cost (approx.): $200–400/session; courses $2,000–10,000, not covered
What the studies found
rTMS for tinnitus: meta-analysis of 16 RCTs
He Z, et al. · Frontiers in Neuroscience · 2025 · N=1,105 (16 RCTs) · Meta-analysis
Active rTMS beat sham post-treatment (THI MD −11.5) and at 1 month (−11.0). At 6 months the two big meta-analyses DISAGREE: this 2025 analysis found no significant effect (MD −4.26, 95% CI −10.28 to 1.76), while the 2020 meta-analysis (29 RCTs, N=1,228; PMID 33228598) found a small significant one (−6.53, 95% CI −11.41 to −1.66).
Either way, even the significant estimates sit at or below the ~7-point THI clinical-meaningfulness threshold — the durability and magnitude problems are unresolved, not settled in either direction.
rTMS for chronic tinnitus: VA randomized sham-controlled trial (positive)
Folmer RL, et al. · JAMA Otolaryngology–Head & Neck Surgery · 2015 · N=70 randomized, 64 analyzed (32/arm) · Randomized placebo(coil)-controlled trial; 1-Hz rTMS × 10 consecutive workdays; NCT01104207
POSITIVE: responders 18/32 (56%) active vs 7/32 (22%) placebo, p<.005. Distress/severity outcome (TFI) — not loudness.
One half of the field's central contradiction: this positive trial coexists with the larger multicenter negative Landgrebe 2017 trial — which is why the platform labels rTMS replication 'Conflicting results'.
rTMS for chronic tinnitus: multicenter randomized sham-controlled trial (negative)
Landgrebe M, et al. · Brain Stimulation · 2017 · N=163 randomized (75 real / 78 sham) · Multicenter randomized sham-controlled trial; 1-Hz left temporal rTMS, 10 sessions; ISRCTN89848288
NEGATIVE: TQ change −0.5 (real) vs +0.5 (sham); adjusted difference −1.0 [95% CI −3.2, 1.2], p=0.36. Well tolerated; not superior to sham.
The largest multicenter rTMS tinnitus trial. Together with Folmer 2015 (positive), it defines the conflicting replication picture for rTMS.
AAO-HNSF Clinical Practice Guideline: Tinnitus
Tunkel DE, Bauer CA, Sun GH, et al. · Otolaryngology–Head and Neck Surgery · 2014 · N=Guideline (23-author multidisciplinary panel) · Clinical practice guideline (US)
RECOMMENDS: hearing-aid evaluation (with hearing loss) and CBT for persistent bothersome tinnitus. OPTION: sound therapy ('may recommend'). AGAINST routine use: medical therapy (antidepressants, anticonvulsants, anxiolytics, intratympanic drugs), dietary supplements (Ginkgo, melatonin, zinc), and rTMS. NO RECOMMENDATION: acupuncture.
Guidelines are consensus documents, not new trial data. Where the three major guidelines disagree — chiefly on sound therapy (AAO-HNSF: option; NICE and the European guideline: research-only; the German S3 guideline: against sound generators) — this platform shows the disagreement rather than picking a side. Statement strengths read from the published abstracts; full-text verbatim wording not independently re-read.
Related clinical trials
- Navigated rTMS for chronic tinnitus — Recruiting
- Personalized-target continuous theta-burst stimulation — Recruiting
Tracked trials are research in progress, not recommended treatments.
Related treatments
- tDCS / tACS / tRNS (transcranial electrical stimulation) — Cheap and safe, possibly a mild adjunct — the evidence is too heterogeneous to say more.
- Transcranial focused ultrasound (emerging) — Focused ultrasound can reach deep brain circuits no coil can — first tinnitus study starting at Oxford; no…
Evidence last reviewed: 2026-09-03 · Evidence included through: 2026-09-03 · Confidence: high. Open the interactive evidence profile.
This page summarizes published research for education. It is not medical advice; it cannot say what will work for any individual. Discuss treatment decisions with a qualified clinician.